Coronavirus. COVID19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Depending on the response to treatment, group 1 will receive Tofacitinib at a dose of 10 mg twice daily (for 5 days) in addition to the 5-day course of Remdesivir (
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: informed written desire and consent to participate in the study Age 18 years or older Hospitalization Severe disease Positive polymerase chain reaction (PCR) test Lung involvement based on CT scan
Exclusion criteria
Exclusion criteria: Death of the patient Physician's diagnosis of not participating in the study History of thrombosis or current thrombosis Suppression of the known immune system Pregnancy and lactation Use of angiotensin converting inhibitors Severe renal, hepatic, respiratory and cardiovascular insufficiency Consumption of cytotoxic drugs Transfer to another hospital
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lactate Dehydrogenase. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Blood Urea Nitrogen. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Creatinine. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Alanine Aminotransferease. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Aspartate Aminotransferase. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Alkaline Phosphatase. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;C-Reactive Protein. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;White Blood Cell. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Neutrophil. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Lymphocytus. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Red Blood Count. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test.;Erythrocyte Sedimentation Rate. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Venous blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory Rate. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Count the respiratory rate per minute.;Percentage of oxygen saturation. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Pulse oximeter.;Heart Rate. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Count the number of heart pumps per minute.;Systolic blood pressure. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Calculate the pressure when the heart contracts.;Body temperature. Timepoint: Before the intervention and one day after the intervention. Method of measurement: Based on thermometer.;Performance status. Timepoint: Before the intervention and one day after the intervention. Method of measurement: According to PRIEST checklist.;State of consciousness. Timepoint: Before the intervention and one day after the intervention. Method of measurement: According to PRIEST checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehrdad Dargahi-Malamir
Ahvaz University of Medical Sciences
Outcome results
None listed